MX2009008270A - Polipeptido novedoso que tiene actividad anti-tumoral. - Google Patents

Polipeptido novedoso que tiene actividad anti-tumoral.

Info

Publication number
MX2009008270A
MX2009008270A MX2009008270A MX2009008270A MX2009008270A MX 2009008270 A MX2009008270 A MX 2009008270A MX 2009008270 A MX2009008270 A MX 2009008270A MX 2009008270 A MX2009008270 A MX 2009008270A MX 2009008270 A MX2009008270 A MX 2009008270A
Authority
MX
Mexico
Prior art keywords
tumor activity
amino acid
acid sequence
polypeptide
novel polypeptide
Prior art date
Application number
MX2009008270A
Other languages
English (en)
Inventor
Sunghoon Kim
Jung Min Han
Sang Gyu Park
Yoen Sook Lee
Original Assignee
Imagene Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imagene Co Ltd filed Critical Imagene Co Ltd
Publication of MX2009008270A publication Critical patent/MX2009008270A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un polipéptido novedoso que tiene actividad anti-tumoral a través de la inducción de la apoptosis de la célula endotelial y el uso del mismo; más particularmente, la presente invención se refiere a un método para inducir la apoptosis de la célula endotelial, y para prevenir o tratar el cáncer, que comprende administrar a un sujeto que necesita del mismo una cantidad efectiva de (a) un polipéptido aislado que tiene la secuencia de aminoácidos de SEQ ID NO: 9, o la secuencia de aminoácidos que tiene al menos 90% de homología de secuencia con la secuencia de aminoácidos de SEQ ID NO: 9, o (b) un polinucleótido aislado que codifica el polipéptido de (a).
MX2009008270A 2007-02-01 2008-02-01 Polipeptido novedoso que tiene actividad anti-tumoral. MX2009008270A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89870807P 2007-02-01 2007-02-01
PCT/KR2008/000621 WO2008094012A1 (en) 2007-02-01 2008-02-01 Novel polypeptide having anti-tumor activity

Publications (1)

Publication Number Publication Date
MX2009008270A true MX2009008270A (es) 2009-08-12

Family

ID=39674265

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008270A MX2009008270A (es) 2007-02-01 2008-02-01 Polipeptido novedoso que tiene actividad anti-tumoral.

Country Status (8)

Country Link
US (1) US20110124582A1 (es)
EP (1) EP2121739A4 (es)
JP (1) JP2010526527A (es)
KR (1) KR20090111320A (es)
AU (1) AU2008211884A1 (es)
CA (1) CA2676640A1 (es)
MX (1) MX2009008270A (es)
WO (1) WO2008094012A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101111222A (zh) * 2005-02-01 2008-01-23 伊玛吉恩有限公司 刺激胶原蛋白合成和/或kgf表达的方法
AU2006335748A1 (en) * 2006-01-23 2007-07-26 Imagene Co., Ltd. Novel peptide and use thereof
ES2552773T3 (es) 2009-02-27 2015-12-02 Atyr Pharma, Inc. Motivos estructurales de polipéptidos asociados con la actividad de señalización celular
AU2010226726B8 (en) 2009-03-16 2014-08-14 Pangu Biopharma Limited Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities
CN106474462A (zh) 2009-12-11 2017-03-08 Atyr 医药公司 用于调节炎症的氨酰tRNA合成酶
US20130202576A1 (en) 2010-07-12 2013-08-08 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
AU2012267530A1 (en) * 2011-06-08 2014-01-16 Indiana University Research And Technology Corporation Monoclonal antibody and antigens for diagnosing and treating lung disease and injury
WO2013022982A2 (en) 2011-08-09 2013-02-14 Atyr Pharma, Inc. Pegylated tyrosyl-trna synthetase polypeptides
WO2013086228A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Pegylated aspartyl-trna synthetase polypeptides
WO2013086216A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Improved aspartyl-trna synthetases
US9688978B2 (en) 2011-12-29 2017-06-27 Atyr Pharma, Inc. Aspartyl-tRNA synthetase-Fc conjugates
WO2013123432A2 (en) 2012-02-16 2013-08-22 Atyr Pharma, Inc. Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
DK3460054T3 (da) 2013-03-15 2021-01-18 Atyr Pharma Inc Histidyl-tRNA-syntetase-Fc-konjugater
CA3060514A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
KR102292069B1 (ko) * 2020-10-19 2021-08-20 대한민국 돌돔 인지질분해효소 유래의 항균 펩타이드를 유효성분으로 함유하는 암 치료용 약학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155214A (en) * 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
US5556645A (en) * 1990-01-12 1996-09-17 Bockman; Richard Methods of enhancing wound healing and tissue repair
US5981606A (en) * 1991-03-01 1999-11-09 Warner-Lambert Company Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same
US5641867A (en) * 1993-09-29 1997-06-24 The Trustees Of Columbia University In The City Of New York Antibody which specifically binds to endothelial-monocyte activating polypeptide II
US6391311B1 (en) * 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
US6800286B1 (en) * 1998-08-19 2004-10-05 The Regents Of The University Of Colorado Chimeric fibroblast growth factor proteins, nucleic acid molecules, and uses thereof
US6306612B1 (en) * 1998-11-13 2001-10-23 Children Hospital Los Angeles Methods of facilitating vascular growth
AU5114000A (en) * 2000-06-14 2001-12-24 Imagene Co., Ltd. P43 anti-tumor therapeutic agent and three dimensional structure of its cytokinedomain
KR100405919B1 (ko) * 2001-06-05 2003-11-14 주식회사 이매진 ｐ43의 Ｎ-말단 펩타이드를 유효성분으로 하는 면역증강용 약학조성물
KR100515016B1 (ko) * 2002-07-22 2005-09-15 재단법인서울대학교산학협력재단 ｐ43을 유효성분으로 하는 창상 치료용 약학적 조성물
CN101111222A (zh) * 2005-02-01 2008-01-23 伊玛吉恩有限公司 刺激胶原蛋白合成和/或kgf表达的方法
AU2006335748A1 (en) * 2006-01-23 2007-07-26 Imagene Co., Ltd. Novel peptide and use thereof

Also Published As

Publication number Publication date
AU2008211884A1 (en) 2008-08-07
US20110124582A1 (en) 2011-05-26
WO2008094012A1 (en) 2008-08-07
EP2121739A1 (en) 2009-11-25
JP2010526527A (ja) 2010-08-05
CA2676640A1 (en) 2008-08-07
KR20090111320A (ko) 2009-10-26
EP2121739A4 (en) 2010-03-10

Similar Documents

Publication Publication Date Title
MX2009008270A (es) Polipeptido novedoso que tiene actividad anti-tumoral.
MX2008009493A (es) Peptido novedoso y uso del mismo.
IN2012DN03824A (es)
MX339277B (es) Agente inductor de inmunidad.
MX2009011179A (es) Variantes de enzimas asparaginasas y sus usos.
NZ603348A (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
EA200901432A1 (ru) Новые аспарагиназы и их применение
MX2011011215A (es) Polipeptido que degrada carbohidratos y usos del mismo.
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
NZ603901A (en) Vectors and sequences for the treatment of diseases
NZ595501A (en) Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
MX2012015142A (es) Polipeptidos que tiene actividad beta-glucosidasa y usos del mismo.
MX2012015139A (es) Polipéptido que tiene o que ayuda en la actividad de degradación del material de carbohidratos y usos del mismo.
TN2012000393A1 (en) Agonist dr5 binding polypeptides
NZ623576A (en) Tfpi inhibitors and methods of use
NZ597306A (en) Mesenchymal stem cell differentiation
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
MX2021008131A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
HK1089788A1 (en) A recombinant protein with cancer suppression action, its encoding gene and use
MX2015003310A (es) Moleculas de union il-17a novedosas y usos medicos de las mismas.
MX2019009551A (es) Enzima lipolitica para usarse en horneado.
EP4306123A3 (en) Saposin-a derived peptides and uses thereof
NZ610620A (en) Inhibitors of apoptosis and uses thereof
EP2114431A4 (en) ARAZYME-CONTAINING COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER
PH12021551372A1 (en) Human alpha-galactosidase variants

Legal Events

Date Code Title Description
FA Abandonment or withdrawal